CIA
ACAD icon

Concurrent Investment Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Concurrent Investment Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$709K Sell
28,041
-1,364
-5% -$30K 0.01% 1194
2026
Q1 		$655K Sell
29,405
-14,052
-32% -$336K 0.01% 1089
2025
Q4 		$1.16M Buy
43,457
+27,257
+168% +$651K 0.01% 765
2025
Q3 		$346K Buy
16,200
+1,781
+12% +$42.1K 0.01% 1092
2025
Q2 		$311K Sell
14,419
-462
-3% -$8.59K 0.01% 1054
2025
Q1 		$247K Buy
+14,881
New +$270K 0.01% 1019

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Concurrent Investment Advisors's ACAD Position: Q2 2026 in Review

Concurrent Investment Advisors reduced its Acadia Pharmaceuticals (ACAD) stake by 4.6% in Q2 2026, selling an estimated $30K and leaving 28,041 shares worth $709K. The position accounts for 0.01% of the portfolio, ranked #1194.

Concurrent Investment Advisors first reported a position in ACAD in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.16M in Q4 2025. 352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Concurrent Investment Advisors held 28,041 shares of Acadia Pharmaceuticals worth $709K as of Q2 2026.
  • Concurrent Investment Advisors sold 1,364 Acadia Pharmaceuticals shares in Q2 2026, an estimated $30K.
  • Acadia Pharmaceuticals made up 0.01% of Concurrent Investment Advisors's portfolio in Q2 2026, its #1194 holding.
  • Concurrent Investment Advisors first reported a position in Acadia Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • Concurrent Investment Advisors's Acadia Pharmaceuticals position peaked at $1.16M in Q4 2025.
  • 352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Concurrent Investment Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.